Aerie Acquires Envisia Technology for $25M to Advance Retinal Program

October 6, 2017: By Jon Swedien

AerieAerie Pharmaceuticals announced Oct. 5 that it has acquired from Envisia Therapeutics the rights to use its PRINT technology in ophthalmology, along with certain other assets.

The PRINT technology is Envisia’s proprietary system for sustained-release products.

Under the terms of the agreement, Envisia will receive $25 million upfront in a combination of cash and Aerie common stock. Envisia, of Durham, North Carolina, could earn more based on certain product approval milestones, Aerie said.

Aerie, of Irvine, California, said it intends to use the technology to accelerate the advancement of its pipeline to treat conditions in the back of the eye, such as wet age-related macular degeneration and diabetic retinopathy.

Aerie’s initial focus will be in using PRINT to manufacture injectable implants containing its preclinical product candidate known as AR-13154, a potential wet AMD treatment.

This potentially could be done in conjunction with a biodegradable polymer from DSM, a Netherlands-based company that Aerie struck a collaborative agreement with in July.

In addition, Aerie acquired the intellectual property rights relating to ENV1105, Envisia’s preclinical dexamethasone steroid product candidate for the treatment of diabetic macular edema, which also uses the PRINT technology, Aerie said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales